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2 SUMMARY 
PIM1 kinase (proviral insertion site for moloney leukemia virus 1) is expressed in 
different cell types, promoting cell growth, migration, differentiation and survival. This 
constitutively active serine-threonine kinase is mainly regulated at transcriptional and 
translational levels. As a proto-oncogene, PIM1 expression has been correlated with 
drug resistant tumors, tumor growth and cancer cell metastasis. It facilitates cell 
proliferation, migration and anti-adhesion.  
Interactions between tumor cells and vascular endothelium are important for tumor 
growth. In the quiescent condition the endothelial monolayer provides a regulated 
barrier between the tissue and the blood stream. On the other hand sprouting from 
the endothelial monolayer is the initial starting point for the angiogenic process, which 
involves proliferation, migration and formation of endothelial tubes. Angiogensis is not 
only a prerequisite for tumor growth but also promotes and facilitates migration, 
invasion and metastatic spread of malignant cells.  
Even though plenty of studies have investigated PIM1’s function in cancer, little is 
known how PIM1 influences endothelial proliferation and so far there are no data on 
its contribution to barrier integrity of the endothelial monolayer. 
In the first part of this thesis I have investigated, how PIM1 contributes to endothelial 
proliferation and whether it confers resistance to rapamycin-induced growth arrest. 
We found that Pim1-/- mouse aortic endothelial cell (MAEC) proliferation was 
significantly more sensitive to rapamycin, compared to wildtype cell growth rates. 
Interestingly, rapamycin treatment was accompanied with higher PIM1 protein levels 
in the cytosol and in the nucleus. Generation of an expression system consisting of 
Pim1 c-terminal truncation mutants revealed a critical region responsible for nuclear 
localization of the protein. Truncations beyond a specific Serine, Serine 276, located 
to the nucleus, as also observed, when cells were treated with rapamycin. 
Reexpression of this mutant in Pim1-/- cells significantly increased proliferation. In 
summary we show, that nuclear PIM1 alone is sufficient to increase endothelial cell 
proliferation, which could explain the higher resistance of Pim1 wildtype cells to 
rapamycin.  
In the second part of this thesis I have investigated if PIM1 also contributes to barrier 
integrity of the endothelial monolayer. Pim1-/-  MAEC displayed decreased migration 
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in wound closure assays, slowed cell detachment after trypsinization and increased 
electrical resistance across the endothelial monolayer. Reintroduction of Pim1-cDNA 
into Pim1-/- MAEC significantly restored wildtype adhesive characteristics. Pim1-/- 
MAEC displayed enhanced focal adhesion and adherens junction structures as 
suggested by immunostainings for vinculin and -catenin. Transcriptome analysis 
revealed junctional molecules such as Cadherin 13 and matrix components such as 
Collagen 6a3 to be highly upregulated in Pim1-/- cells. Intriguingly, extracellular matrix 
deposited by Pim1-/- cells alone was sufficient to induce the hyperadhesive 
phenotype in wildtype endothelial cells. Taken together these results show, that loss 
of Pim1 induces a strong adhesive phenotype by enhancing endothelial cell-cell and 
cell-matrix adhesion by the deposition of a distinct extracellular matrix. 
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3 ZUSAMMENFASSUNG 
Die Protein Kinase PIM1 (proviral insertion site for moloney leukemia virus 1) 
begünstigt in verschiedenen Zelltypen, Wachstum, Migration, sowie deren 
Fortbestand. Sie zählt zu den konstitutiv aktiven Kinasen und wird hauptsächlich auf 
transkriptioneller und translationeller Ebene reguliert. Eine hohe zelluläre Pim1 
Expression korreliert mit einer schnelleren Zellvermehrung, erhöhten Migrationsraten 
der einzelnen Zellen und einer Abnahme der Zelladhärenz, eine Eigenschaft die 
PIM1 zum Proto-Onkogen macht. Diese Faktoren erhöhen die Resistenz der Zelle 
gegenüber medikamentöser Behandlung und fördern Tumorwachstum und 
Metastasierung.  
Wie schnell und ob überhaupt ein Tumor wächst, wird zu einem bedeutenden Teil 
durch das Wechselwirken von Tumorzellen und dem vaskulären Endothel bestimmt.  
Im Ruhezustand fungiert das Endothel, bestehend aus einer einzigen Zellschicht, als 
Barriere zwischen dem Blutgefässsystem und dem Gewebe. Andererseits ist das 
aussprossen des Endothelzellschicht der Beginn der sogenannten Angiogenese. Bei 
diesem Prozess beginnen die Endothelzellen zu proliferieren und zu migrieren und 
bilden so neue Gefässe. Diese sogenannte Tumorangiogenese fördert jedoch nicht 
nur das Wachstum des kanzerösen Gewebes per se, sondern ermöglicht auch die 
Migration, die Invasion und die Metastasierung von malignen Zellen in die Peripherie 
und somit andere Organe des Körpers.  
Obwohl schon viele Studien veröffentlicht wurden, die sich mit der Funktion der PIM1 
Kinase in Tumoren befassen, ist eigentlich wenig bekannt darüber, wie PIM1 das 
endotheliale Zellwachstum ankurbelt und bis jetzt nichts, ob PIM1 die endotheliale 
Barrierefunktion beeinflusst.  
Im ersten Teil dieser Studie habe ich mich zum einen mit der Frage befasst, wie 
PIM1 das Endothelzellwachstum beeinflusst und zum anderen ob es zudem eine 
gewisse Resistenz der Zellen gegenüber Rapamycin, einem Zellwachstumshemmer, 
hervorrufen kann. Wir explantierten Aorten aus Wildtyp und Pim1-/- Mäusen und 
extrahierten aus diesen Endothelzellen. Im Vergleich zu endothelialen Wildtyp Zellen, 
waren Pim1-/- Zellen bezüglich ihrer Wachstumsrate signifikant sensitiver gegenüber 
Rapamycin. Wir beobachteten, dass die Behandlung von Wildtypzellen mit 
Rapamycin zu einer grösseren Anzahl Zellen mit zytosolischem und nukleärem PIM1 
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führt. In der Folge entwickelten wir ein auf Plasmiden basierendes System zur 
Expression von Pim1 in Pim1-/- Zellen. Wir verkürzten das c-terminale Ende der Pim1 
Kinase schrittweise und exprimierten diese Konstrukte in Pim1-/- Zellen. Dadurch 
fanden wir heraus, dass das Fehlen des c-Terminus ab Serin 276 zu einer nukleären 
Lokalisation von PIM1 führt, wie wir das auch bei rapamycin behandelten Wildtyp 
Zellen beobachteten. Wird diese Mutante nun in Pim1-/- Zellen exprimiert, führt das zu 
einer signifikant höheren Wachstumsrate verglichen mit Pim1-/- Zellen die das 
ungekürzte, also das Wiltyp Pim1 exprimieren. Zusammenfassend könnte man 
sagen, dass allein nukleäres PIM1 ausreicht um den endothelialen Zellwachstum zu 
erhöhen. Dies könnte auch die erhöhte Resistenz von Wildtyp Zellen gegenüber 
Rapamycin erklären. 
Im zweiten Teil dieser Studie beschäftigte ich mich mit der Funktion, die PIM1 bei der 
Aufrechterhaltung der endothelialen Barriere einnimmt. Zellmigrationsexperimente 
zeigten, dass Pim1-/- Zellen erheblich langsamer migrieren und im Vergleich zu 
Wiltyp Zellen längere Inkubationszeiten mit Trypsin notwendig sind, um sie von der 
Kulturschalenoberfläche abzulösen. Zudem zeigten Messungen, dass ein Pim1-/- 
Zellrasen einen viel grösseren elektrischen Widerstand hat als dass dies bei Wildtyp 
Zellen zu beobachten ist. Wurde jedoch das fehlende PIM1 in Pim1-/- Zellen in Form 
einer Pim1-cDNA wieder zugegeben, wiesen die Zellen wiederum die adhesiven 
Eigenschaften des Wildtyps auf. Mit Immunfluoreszenzbildern konnten wir zeigen, 
dass Vinculin und -catenin in Pim1-/- Zellen, Proteine die in focal adhesions und 
adherens junctions vorzufinden sind, ausgeprägtere Strukturen bilden. Wir fanden 
viel mehr Vinkulin in Pim1-/- Zellen vor und die -catenin Färbungen in den adherens 
junctions waren viel länger als in den Wildtyp Zellen. Eine vergleichende 
Genexpressionsanalyse zeigte, dass tatsächlich viele Gentranskripte in Pim1-/- Zellen 
hochreguliert sind, die für Moleküle kodieren welche in die Zelladhäsion involviert 
sind. Unter anderem sind dies Cdh13, ein Protein der Zell junctions oder Col6a3, ein 
Protein der extrazellulären Matrix. Interessanterweise konnten wir letztlich zeigen, 
dass allein die von Pim1-/- Zellen ausgeschüttete Matrix genügt, um bei darauf 
wachsenden Wildtyp Zellen einen adhesiven Phänotypen zu induzieren.       
Somit kann man sagen, dass das Fehlen von Pim1 einen extrem adhesiven 
Phänotypen hervorruft. Dieser ist auf eine stärkere Zell-Zell, wie auch Zell-Matrix 
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Adhäsion zurückzuführen, die durch Sezernieren einer spezifischen Matrix 
hervorgerufen wird.    
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4 INTRODUCTION 
 Structure and functions of blood vessels 4.1
The circulatory system delivers essentials such as oxygen or nutrients to and carries 
waste products away from our organs and tissues. The functional units of this 
transportation system are the blood vessels, more precisely arteries, capillaries and 
veins, that altogether measure a stunning 50’000 km in length.  
4.1.1 Assembly of the vessel wall 
Three main layers composed of cells and matrix components form the vessel lumina 
of arteries and veins: the tunica externa, the tunica media and the tunica intima 
(Fig.1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) Assembly of an arterial (left) and a venous (right) vessel wall. (B) Three
different types of capillaries. A continous (left), a fenestrated (middle) and a sinusoidal
capillary. Fig. 1A by Aumüller [3]; Fig. 1B adapted from Yale systems cell biology. 
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The outermost layer, the tunica externa or adventitia, contains connective tissue and 
is relatively thin in arteries or arterioles when compared to larger vessels: In the 
aorta, the adventitia contains small blood vessels, the vasa vasorum, that feed the 
larger vessel walls with nutrients. The second layer, the tunica media provides 
mechanical support against pulsatile blood flow. The tunica media is composed of  
smooth muscle cells embedded in a mesh of collagen and elastic fibers, that regulate 
blood flow through vasoconstriction and –dilation. The innermost layer facing the 
lumen is the tunica intima, composed by the stratum subendotheliale, which provides 
an anchoring basal lamina for a single layer of cells, the endothelium. Capillaries 
consist of a connected endothelium surrounded by a basement membrane and 
connective tissue, which is wrapped by pericytes (Fig.1B). Capillaries can be further 
divided into three types based on the morphology of the endothelial layer: 
Continuous, fenestrated and sinusoidal capillaries. The least permeable capillaries 
are characterized by a continuous endothelium. Fenestrated capillaries provide a 
continuous basement membrane, but manifest gaps between endothelial cells. The 
third type of capillaries, i.e., the sinusoids, are characterized by a discontinuous 
endothelium, exhibit large gaps in the endothelial monolayer and also a 
discontinuous basement membrane.  
4.1.2 Endothelial barrier function  
The endothelial monolayer serves as a highly regulated permeability barrier to ensure 
a controlled exchange of molecules through the vessel wall [11].  
Two pathways ensure the controlled exchange between the vessel lumen and the 
interstitial space: The trans- and the paracellular pathway. In the resting endothelium 
transendothelial flux mainly occurs transcellularly [12]. This caveolae-mediated 
transcytosis from the vessel lumen through the cell to the interstitium is an important 
mechanism to maintain the fluid balance across the endothelial monolayer, the so-
called oncotic pressure [13]. Mechanistically, binding of albumin to its receptor 
induces invagination of microdomains from the cell membrane. These so called 
caveolae separate as small vesicles into the cytoplasm and are able to fuse again 
with the basolateral site of the cell, discharging their cargo to the interstitial space of 
the vessel [14]. The paracellular pathway is pivotal in inflammation and cancer cell 
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extravasation [15]. Paracellular transport or paracytosis is regulated by 
interendothelial gap-, tight- and adherens junctions. Gap junctions serve as channels 
between the cells of the monolayer, to transfer water, ions and small molecules from 
cell to cell. However, tight- and adherens junctions not only restrict the paracellular 
flux, but also promote adhesion between adjacent cells [13]. Importantly, adherens 
junctions, beside their function as gatekeepers and cell adhesion proteins, may also 
regulate vascular homeostasis and contribute to cell proliferation, migration, and 
apoptosis via intracellular signaling cascades [16-18].  
4.1.3 Adherens junctions and focal adhesions  
Cadherins are the structural proteins of adherens junctions, connecting neighboring 
endothelial cells to one another. These single-pass transmembrane glycoproteins 
consist of an extracellular part, directly participating in adhesion, and a cytosolic 
domain that links to the cytoskeleton [19, 20]. Classical cadherins, such as VE-
cadherin, the most prominent cadherin family member in endothelial cells, consist of 
extracellular cadherin (EC) domains. These ectodomain structures require calcium to 
mediate stability and orientation [21]. The ectodomains dimerize on the surface in 
order to bind to neighboring cells (Fig.2) [19]. The intracellular domain of cadherins 
interacts with the cytoskeleton through members of the catenin protein family: α-, -, 
- (also known as plakoglobin) and -catenin (also known as p120) [22]. This 
complex regulates cell adhesion via intracellular signaling. As member of the 
canonical Wnt (wingless-int) signaling pathway, -catenin also acts as a 
transcriptional co-factor in the nucleus. In tumorigenesis for example nuclear -
catenin leads to dissociation of the adherens junctions, and regulates proliferation 
and survival. [23, 24]. Plakoglobin, p120-catenin and -catenin directly interact with 
cadherin, whereas α-catenin associates with plakoglobin and -catenin providing a 
bridge to F-actin (filamentous actin) a major component of the cytoskeleton [25]. 
Structurally α-catenin provides binding sites for catenins and F-actin and is thought to 
stably wire the cytoskeleton and the adherens junction. However, recently α-catenin 
has been shown not to bind F-actin and -catenin simultaneously [26]. 
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Adhesion to the extracellular matrix (ECM) is mediated by a family of cell surface 
receptors, the integrins (Fig.2). Heterodimerization into  and integrin dimers 
confers the intrinsic substrate specificity, enabling the binding to different ligands 
such as collagens, laminins and other components of the ECM. Inside the cell, the 
intracellular part of the integrin receptor binds to talin, that links to the actin 
cytoskeleton via vinculin. Furthermore, the intracellular part of the integrin receptor 
interacts with focal adhesion kinase (FAK), which mediates signal transduction via 
different signaling pathways [27]. Integrin binding results in receptor clustering, actin 
reorganization and recruitment of signaling proteins to the membrane into focal 
adhesions [28]. Such focal adhesion clusters orchestrate cell migration, cell polarity 
and maintain cell growth and survival [29] whereby FAK mediates a dynamic 
crosstalk between focal adhesions and adherens junctions. [30]. 
Figure 2. Simplified scheme of an adherens junction and a focal adhesion. Cell to cell
contact is mediated through homophilic cadherin binding. Cadherin are then linked via
catenins to the vytoskeleton. Cell to matrix contact is mediated via integrin receptors, which
are connected to the cytoskeleton via Talin and vinculin. 
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 Angiogenesis – a dynamic rearrangement of the endothelial barrier  4.2
In the adult, the tunica intima, i.e. the endothelial monolayer, remains quiescent. 
However, angiogenic factors can activate the endothelium in order to form new blood 
vessels from pre-existing ones, a morphogenic process known as angiogenesis [31]. 
Angiogenesis involves endothelial cell division, migration and sprout formation. This 
requires not only the disassembly and assembly of structural proteins at sites of 
endothelial adherens junctions and focal adhesions, but also dynamic changes of the 
endothelial cytoskeleton and the composition of the ECM. Figure 3 shows a model 
how new vessels are formed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the angiogenic process. Angiogenesis starts from
pre-existing vessels, with the conversion of a previously quiescent endothelial cell into a tip
cell. Tip cells form protrusions that invade the surrounding environment followed by a
migrating column, of proliferating endothelial cells, the stalk cells. Within the stalk cells
vacuoles form, which fuse and give rise to the vascular lumen. Upon formation, the new
vessel is stabilized and matured mainly by reestablishment of intercellular adhesion and
coverage with mural cells. Figure by Francavilla [7]. 
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At the early onset of endothelial sprouting, endothelial cells are liberated of mural 
cells [32] and the basement membrane including the ECM through proteolytic 
cleavage [33]. Attracted by proangiogenic stimuli, endothelial tip cells start to 
protrude into the environment. Subsequently, stalk cells, following the leading tip, 
start to proliferate, to support sprout elongation and to form the new vessel lumen. 
Tip cells fuse with neighboring sprouts, a process known as anastomosis, to build a 
new vessel lumen. Finally, during vessel maturation, a new vascular basement 
membrane is deposited and mural cells, i.e., pericytes and vascular smooth muscle 
cells are recruited [34].  
4.2.1 Tumor angiogenesis 
Under physiological conditions angiogenesis occurs during wound healing, tissue 
repair and growth, and in the maternal uterine wall to establish the placental anchor 
[35]. Physiological angiogenesis turns into pathological vessel growth when the fine 
tuned control and negative feedback mechanism over angiogenic subprocesses are 
lost, become chaotic and unregulated [35]. In pathological situations blood vessel 
growth is either excessive, aberrant or insufficient. This is observed in highly 
prevalent diseases such as atherosclerosis, hypertension and cancer [36].  Figure 4A 
displays known mechanisms of tumor vessel growth [9]. Genetic, epigenetic and 
metabolic changes in cancer cells, key steps for cancer progression, can promote the 
‘angiogenic switch’, the critical point when tumor vascularization is switched on. 
Furthermore, hypoxia, due to growth of tumors, is a main trigger for angiogenesis. 
Cells require oxygen and nutrients for their survival and are therefore located within 
100 to 200 m distance of blood vessels, the diffusion limit for oxygen [8]. Beyond a 
critical tumor volume, oxygen and nutrients will not diffuse to cells in the tumor core 
resulting in hypoxia. Hypoxia upregulates expression of hypoxia inducible 
transcription factors (HIFs) in the malignant cells, which then activate gene 
expression of proangiogenic stimuli  (Fig. 5) [9]. Inhibitory molecules can furthermore 
keep the angiogenic balance to the “off” side. Many of these molecules derive from 
larger molecules with no intrinsic inhibitory potential. Upon proteolytic cleavage, the 
products, such as statins, unfold their antiangiogenic properties. In most tumors the 
angiogenic balance remains on the “on” mode, i.e. proangiogenic factors such as 
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VEGF (Vascular endothelial growth factor) or FGF (Fibroblast growth factor) 
predominate antiangiogenic factors (Fig 4B) [37].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast to physiologic blood vessel architecture, the vasculature in tumors is 
unorganized and highly chaotic. The blood vessels display dilated diameters with 
large variations in size, excessive vascular branching with disturbed and 
multidirectional blood flow  [38]. Furthermore, cell-cell adhesion of the endothelial 
monolayer is decreased and the basement membrane incomplete or missing, 
resulting in leaky vessels [9]. This increase in vessel permeability enables tumor 
metastasis resulting in cancer cell extravasation into the circulatory system [39].  
 
Figure 4. (A) Cellular mechanisms of tumor (lymph) angiogenesis. Tumor vessels grow by
various mechanisms: (1) the host vascular network expands by budding of endothelial
sprouts or formation of bridges (angiogenesis); (2) tumor vessels remodel and expand by
the insertion of interstitial tissue columns into the lumen of pre-existing vessels 
(intussusception); and (3) endothelial cell precursors (angioblasts) home from the bone
marrow or peripheral blood into tumors and contribute to the endothelial lining of tumor
vessels (vasculogenesis). Lymphatic vessels around tumors drain the interstitial fluid and
provide a gateway for metastasizing tumor cells. (B) Angiogenesis is orchestrated by a 
variety of activators and inhibitors. Activators of endothelial-cell proliferation are shown in 
the red box and inhibitors in the blue box. Figure by Carmeliet [9]. 
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 TOR - the target of rapamycin  4.3
In the search for new antibiotics, the macrolid rapamycin, purified from a bacterial 
strain collected on the island of Rapa Nui (Easter island) was discovered in the 
1960’s, to have strong anti-proliferative and immunosuppressive effects in 
mammalian cells [40]. TOR1/2, the target of rapamycin in yeast, was identified thirty 
years later through mutational search for resistance to cell cycle inhibition by 
rapamycin in budding yeast [41]. The mammalian counterpart was found three years 
later by several groups independently, which is the reason that mammalian target of 
rapamycin (mTOR) is also known as FKBP12-rapamcyin-associated protein (FRAP), 
Figure 5. Because of the irregular pattern and organization of the tumor vasculature, some
cells in tumors are located more than m away from blood vessels and become hypoxic
(red-to-blue gradient indicates progressive hypoxia). Tumor cells survive fluctuations in
oxygen tensions, in part because clones are selected in hypoxic tumors that switch to a
proangiogenic phenotype. HIFs increase transcription of several angiogenic genes and also
affect cellular survival/apoptosis pathways. Box: relationship between the distance of tumor
cells from nearby vessels and their degree of hypoxia (blue symbols) and acidosis (red
symbols) Figure by Helmlinger [8]. Figure by Carmeliet [9]. 
18 
 
rapamycin and FKBP12 target (RAFT), rapamycin target (RAPT), or sirolimus 
effector protein (SEP) [42-46].  
4.3.1 mTOR complex 1 and mTOR complex 2 
mTOR contains a serine/threonine protein kinase domain and exists in two 
multiprotein complexes mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 
2) (Fig.6). Formation of mTORC1 requires assembly of raptor (regulatory associated 
protein of mTOR), PRAS40 (Pro-rich Akt substrate) and deptor (DEP domain-
containing mTOR-interacting protein), mLST8/GL (mammalian lethal with SEC13 
protein 8 /G-protein -subunit like protein) into the complex. mLST8/GL is also a 
component of mTORC2 and appears to be more critical for mTORC2 function [47, 
48]. Besides mLST8 and deptor mTORC2 further requires mSIN1 (mammalian 
stress-activated map kinase-interacting protein 1), PROTOR (protein observed with 
rictor) and rictor (rapamycin-insensitive companion of mTOR) [48, 49] as components 
for proper function. Rapamycin bound to FKBP12 (FK506-binding protein) effectively 
and rapidly inhibits mTORC1. mTORC2 is not acutely inhibited by rapamycin, 
however long-term or high-dose treatment also affects mTORC2 assembly [50].  
4.3.2 The mTOR pathway 
The mTOR pathway is a central regulator of cell growth and proliferation, but also 
regulates cell survival, motility and metabolism. mTOR integrates different signals 
and functions [51]. Four major inputs have been implicated in mTOR signaling: 
growth factors, energy, nutrients and stress [52] (Fig.6). 
mTORC1 integrates signals from stress, energy, growth factors and amino acids to 
promote cell growth, protein synthesis, cell proliferation and cell metabolism [53, 54]. 
With the exception of amino acids, all other signals modulate the activity of the TSC1-
TSC2 (tuberous sclerosis complex1/2) complex, which negatively regulates 
mTORC1. By blocking TSC1/2 activity, growth promoting signals activate mTOR 
signaling, whereas stress signals inactivate the mTOR cascade. The two major 
downstream kinase targets of mTORC1 are S6K (ribosomal S6 protein kinase 1) and  
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4EBP (eukaryotic initiation factor (eIF) 4E-binding protein 1), contributing to cell 
growth (protein synthesis) and cell cyle progression [4, 48]. Activated mTORC1 also 
triggers a negative feedback loop via S6K: Activated S6K phosphorylates insulin 
receptor substrate 1 (IRS-1), leading to its proteasomal degradation and partial 
inhibition of PI3K/AKT signalling [55].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AKT/PKB (protein kinase B) is a protein downstream of PI3K signalling. Upon growth 
factor signaling AKT is phosphorylated by PDK1 (phosphoinositide-dependent kinase 
1), which is facilitated by mTORC2 activity. Complete activation of AKT requires 
additional phosphorylation of AKT on Ser473 by mTORC2. [56]. However upstream 
regulators of mTORC2 are largely unknown. Recent data suggest that mTORC2 
activity requires association with ribosomes promoted by PI3K [57]. Finally, mTORC2 
Figure 6. Simplified representation of mTOR signalling. mTORC1 and mTORC2
integrate extracellular inputs such as energy, stress, nutrients and growth factors, to
regulate cell growth, proliferation and survival. Figure adapted from Foster [4].   
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activity affects several cellular processes such as cell proliferation, cell survival, and 
organization of the actin cytoskeleton [58].    
Thus, the mTOR pathway regulates many major cellular processes and is implicated 
in an increasing number of pathological conditions, including cancer, obesity, type 2 
diabetes, and neurodegeneration. 
 PIM1 and the family of PIM kinases 4.4
PIM1 is a constitutively active serine threonine kinase [59] discovered as a proviral 
integration site for moloney murine leukemia viruses. The family of PIM kinases 
consists of three members PIM1, 2 and 3 (Fig.7) [60-62].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PIM kinases are highly conserved between species, share high homology to each 
other and exert complementary functions [1, 62]. Mice deficient for all three Pim 
kinases displayed reduced body size and impaired responses to hematopoietic 
growth factors, but were viable and fertile [1]. This finding suggests that PIM kinases, 
Figure 7. Pim genes are located at different chromosomal locations in the mouse and
human genome, as indicated by black numbers and numbers in orange boxes, respectively.
Pim mRNA transcripts are encoded by 6 exons (dark blue boxes) with large 5′ and 3′
untranslated regions (UTRs; white boxes) containing a G/C-rich region (light blue lariat) and
five copies of AUUUA destabilizing motifs (orange circles), respectively [1]. Different protein
isoforms are synthesized using alternative translation initiation sites (solid and dashed
arrows) and additional codons present at the 5′ of these mRNAs are depicted as light blue
boxes. PIM protein isoforms have different molecular masses but retain their
serine/threonine kinase activity [2]. Pim kinases have no regulatory domains and their highly
conserved kinase domain is indicated by a white box. Figure by Nawjin [10]. 
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including PIM1, are important but dispensable factors for growth factor signaling. 
Therefore, PIM kinases, which have proto-oncogenic activity, also emerged to 
interesting targets in cancer therapy (see section 4.4.1). In healthy conditions PIM 
kinases are expressed at low levels and in different cell lineages, such as 
hematopoietic cells, cardiomyocytes or vascular smooth muscle cells [63-65]. In 
endothelial cells PIM1 is transiently expressed during in vivo angiogenesis and 
induced by Vascular endothelial growth factor (VEGF) in human umbilical vein 
endothelial cells (HUVECs). Furthermore, PIM1 silencing impaired vascular 
endothelial growth factor-A (VEGF-A)-induced proliferation and migration and 
inhibited capillary formation on matrigel and endothelial cell sprouting in HUVECs 
[66]. 
PIM1 is involved in several signal transduction pathways (see section 4.4.1). Many 
different cytokines activate Pim1 expression through growth factor signaling 
pathways, like the Janus kinase and signal transducer and activator of transcription 
(JAK–STAT) pathway [67, 68]. Due to its anti-apoptotic activity PIM1 is referred to as 
a proto-oncogene involved in the progression of different cancer types.  
4.4.1 The Pim1 oncogene 
PIM1 kinase expression is increased in different tumours from epithelial and 
haemotopoetic origin [10]. In most haematopoetic malignancies PIM1 expression 
correlates with a poor prognosis [69, 70], however in pancreatic non-small-cell lung 
cancer and in pancreatic ductal carcinoma PIM1 expression inversely correlated with 
prognosis [71, 72]. Elevated Pim1 mRNA and protein levels correlate with the 
metastatic potential of tumors by facilitating migration and anti-adhesion as shown in 
tongue squamous cell carcinoma [73], gastric cancer [74] and in lymph node 
metastasis [75]. Vice versa, inhibition of PIM1 kinase activity diminished cancer cell 
migration and invasion in vitro [75]. 
Since the discovery of Pim1 as a proviral insertion of moloney leukemia virus several 
different modes of action have been shown of how PIM1 contributes to tumorigenesis 
(Fig.8): PIM1 promotes cell growth, migration, differentiation and survival through 
phosphorylation of different substrates [76]. PIM1 promotes cell cycle progression by 
phosphorylation of the cell cycle inhibitors p27Kip1 and p21Cip1/WAF1 [77, 78]. p27Kip1 
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phosphorylation induced cytoplasmic localization and subsequent proteasomal 
degradation of cycline-dependent-kinase inhibitor. p21Cip1/WAF1 also localized to the 
cytoplasm once phosphorylated by PIM1 kinase. Another substrate of PIM1 is the 
protein kinase Cdc25 C-associated kinase 1 (C-TAK1). The phosphorylation of C-
TAK1 significantly decreased its ability to phosphorylate and inactivate Cdc25C, a 
protein that promotes cell cycle progression [79]. Suppressor of cytokine signalling 
(SOCS) proteins are essential for T-cell differentiation. PIM1 physically interacts with 
SOCS family members and potentiates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
their inhibitory effect on STAT5 mediated transcription [80]. Another PIM1 substrate 
is the pro-apoptotic protein B-cell-lymphoma-2-antagonist of cell death (BAD). PIM1 
was found to phosphorylate BAD on serine 112, a gatekeeper site for its inactivation. 
This suggests a possible mechanism for PIM1 to enhance Bcl-2 activity and thereby 
to promote cell survival [81]. Furthermore, PIM1 was found to be a regulator of 
CXCL12-CXCR4-mediated homing and migration of hematopoietic stem cells. Bone 
marrow cells from Pim1-/-  expressed less CXC-Motive-Chemokinereceptor 4 
Figure 8. Different phosphorylation targets of PIM1 signalling and their functional outcome.
In red the ATP binding pocket, which is the target for small molecule PIM1 kinase inhibitors.
Figure by Stavropoulou [5]. 
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(CXCR4) and PIM1 activity was essential for cell migration towards a CXCL12 
gradient [82]. 
PIM1 contains an ATP binding pocket as usual for protein kinases, however PIM1 is 
kinase is active without phosphorylation. Nevertheless, in the past several PIM1 
kinase inhibitors emerged, binding to this cavity, with in vivo and vitro anti-cancer 
activity [76].  
4.4.2 PIM kinases and mTOR signalling 
The PIM and the mTOR/AKT pathway integrate growth factor signalling and promote 
cell proliferation and survival [10, 52]. They both share phosphorylation targets such 
as BAD or eukaryotic translation-initiation factor 4E (EIF4E) (Fig.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Growth-factor receptors that promote cell survival also activate members of the
JAK and STAT family, resulting in the transcription of a set of genes, including those
encoding the kinases PIM1 and PIM2. The AKT and TOR pathway and the PIM1 and PIM2
pathway function as overlapping, but functionally distinct, regulators of key metabolic
pathways. Similar to TOR, PIM2 regulates key effectors of cap-dependent translational 
initiation, including EIF4E, the translational repressor EIF4E-binding protein 1 (4EBP1), and 
p70 S6 kinase (p70 S6K). Figure by Fox [6]. 
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Furthermore it has been shown that Pim1 depletion decreased the potential of AKT 
mediated survival signaling. In the myocardium of mice PIM1 expression increased 
after acute pathological injury and was also elevated in failing hearts of both mice 
and humans. Cardioprotective stimuli associated with AKT activation induced PIM1  
expression, but could not protect the myocardium in Pim1-/- mice [65]. PIM kinases 
also appear to mediate drug resistance to rapamycin. While it has a minimal effect on 
T cell expansion in vitro and in vivo, cells from Pim1-/- Pim2-/- animals displayed an 
unexpected sensitivity to rapamycin [83]. In animal lymphoma models 
pharmacological blockade of the translation initiation complex was highly effective 
against converging signals of AKT and PIM kinases [84]. Additionally, PIM1 has been 
suggested to increase mTOR activity through phosphorylation of PRAS40 in Factor-
Dependent Cell Progenitor cells (FDCP cells) [85]. Thus the PIM and the mTOR 
pathway seem to have overlapping functions, which can partially substitute for each 
other.  
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5 MATERIALS AND METHODS 
 Cell culture & transfection 5.1
MAECs were isolated from aortae of FVB/N wildtype and Pim1-/- mouse strains as 
described previously [86]. For all experiments cell culture dishes were precoated with 
0.1% gelatine gold (Carl Roth GmbH, Karlsruhe, Germany) for 20 minutes at 37°C. 
Cells were maintained in DMEM (Biochrom, Berlin, Germany) complemented with 
10% FBS, 1% sodium pyruvate, 1% non-essential amino acids and 1% penicillin-
streptomycin (Invitrogen, LuBioScience GmbH, Luzern, Switzerland). Cell numbers 
were assessed with a NucleoCounter® NC-100™ (Chemometec, Allerød, Denmark). 
In all experiments ~ 8×104 cells/cm2 were seeded, washed with phosphate-buffered 
saline (PBS) (Invitrogen, Carlsbad, CA) after 24 hours and trypsinized (TripLE 
express, Invitrogen, Carlsbad, CA) for further processing. The percentage of 
adherent cells was calculated as follows: [Total cell count – detached cell count]/Total 
cell count. Light micrographic pictures were acquired using an IX71 inverted 
microscope (Olympus, Volketswil, Switzerland). Compound K00486 was applied at a 
concentration of 100nM to wildtype cells. For PIM1 overexpression human cDNA 
encoding PIM1 was subcloned into a pCMV-Tag2A or a pdsRED C1 expression 
vector (kind gift of Jürg Schwaller, Department of Biomedicine, University Hospital, 
Basel, Switzerland) and cell transfection was performed with 50ng of vector/reaction 
using a basic endothelial cells nucleofector kit in a Nucleofector II device (Amaxa 
Biosystems, Cologne, Germany) according to the manufacturers protocol.  
 Wound healing assay 5.2
Pim1 wildtype and knockout MAEC were grown to confluency in 6-well plates and 
wounded with a 200 l pipette tip along a ruler. Wounded monolayers were washed 
three times with growth medium before further incubation. At the indicated time points 
(0, 4, 8 and 24 hours), monolayers were photographed 3 times for each well at 20x 
magnification. Wound width was measured on hard copy prints of the images. 
Individual cell paths were determined for leading-edge cells along five uniformly 
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spaced lines along the wound edge. Initial wound at 0 hours was defined as 0% 
wound closed, total closure was defined as 100% wound closed.  
 Matrix exchange experiment 5.3
~ 8×104 cells/cm2 wildtype and Pim1-/- MAECs were grown on 6-well plates (BD 
Biosciences, Franklin Lakes, NJ) for 24 hours. The cells were lysed with 25mM 
ammoniumhydroxyde (Sigma-Aldrich, St. Louis, MO) in PBS while leaving the 
extracellular matrix (ECM) intact. Wildtype cells grown on wildtype or Pim1-/- ECM for 
24 hours were then trypsinized for 1, 2 or 3 minutes. To collect all the cells at each 
time point the cell layers were washed 3 times with PBS and the cell numbers in the 
collected supernatants were assessed and percentage of adherent cells was 
calculated as described above.  
 Immunoblotting 5.4
Total cell lysates were prepared using RIPA buffer as described before [87]. After 
SDS-PAGE, proteins were transferred onto polyvinylidene fluoride (PVDF) 
membrane (Millipore, Billerica, MA). The membrane was blocked with 4% skim milk 
powder in TBS-Tween solution or 4% BSA and probed with following antibodies: 
rabbit polyclonal anti-PIM1 (Cell Signaling Technology, Danvers, MA), primary mouse 
monoclonal to vinculin (abcam, Cambridge, MA), rabbit polyclonal anti--catenin (Cell 
Signalling Technology, Danvers, MA), rabbit polyclonal anti--Tubulin (Cell Signalling 
Technology, Danvers, MA), rabbit polyclonal anti-Histone H3 (Cell Signalling 
Technology, Danvers, MA), rabbit polyclonal anti-T-cadherin (Sigma-Aldrich, St. 
Louis, MO), rabbit polyclonal anti-COL6A3 (Abnova Coorporation, Neihu, Taipei), 
mouse monoclonal anti-FLAG (Sigma-Aldrich, St. Louis, MO) and mouse monoclonal 
anti--actin (Sigma-Aldrich, St. Louis, MO). Anti-mouse or rabbit-HRP-conjugated 
IgGs (Cell Signalling Technology, Danvers, MA) were used for visualization of 
relevant proteins on X-ray films by a chemiluminescence reaction (Thermo Scientific, 
Waltham, MA).  
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 Fluorescence imaging 5.5
The cells were fixed in 4% paraformaldehyde for 20 minutes at 37°C on coverslips 
(Karl Hecht AG, Sondheim, Germany) and then permeabilized with 0.5% Triton X-
100 in PBS for 10 min. After blocking for 45 minutes with goat serum the cells were 
incubated with the following antibodies: mouse monoclonal to PIM1 (Santa Cruz, 
Santa Cruz, CA), mouse monoclonal to vinculin (abcam, Cambridge, England),  
rabbit polyclonal anti--catenin (Cell Signalling Technology, Danvers, MA), mouse 
monoclonal anti-FLAG (Sigma-Aldrich, St. Louis, MO) and rabbit polyclonal COL6A3 
antibody (Abnova Coorporation, Neihu, Taipei). After 3 washing steps cells were 
incubated with Alexa Fluor 555-conjugated secondary antibody (Invitrogen). F-actin 
was probed with Alexa Fluor 488 phalloidin and the nuclei were stained with Hoechst 
33342 (Invitrogen). The coverslips were then mounted with FluorSave™ (Merck, 
Darmstadt, Germany) on glass slides (Thermo Scientific, Waltham, MA). 
Fluorescence imaging was performed using a ZEISS Axioskop fluorescence 
microscope (Carl Zeiss AG, Oberkochen, Germany) and a confocal laser scanning 
microscope Leica SP5 (Leica, Wetzlar, Germany). 
 qRT-PCR 5.6
RNA was isolated using a RNAeasy Mini kit (Qiagen, Hilden, Germany), followed by 
a on column DNA digestion (Qiagen, Hilden, Germany). cDNA was transcribed from 
total RNA using Omniscript RT kit (Qiagen, Hilden, Germany) and random primers 
(Roche, Basel, Switzerland). To control for DNA contamination in the qRT-PCR, for 
each sample a control reaction missing reverse transcriptase was additionally 
amplified. Primers for microarray validation and genotyping wildtype and Pim1-/- cells 
(supplementary material table S1, section 13) were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3). Primers for validation were tested by cDNA dilution 
series to obtain optimal reaction conditions. qRT-PCR was performed using an 
iCycler iQ Real Time PCR Detection System (Biorad, Reinach, Switzerland) and iQ™ 
SYBR® Green Supermix (Biorad). 250ng cDNA/reaction was amplified using 
indicated primers (Table S1) in duplicates in a final reaction volume of 25l. Each 
representative reaction was loaded on an agarose gel for amplicon length analysis 
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and additionally the melting curve was analyzed. The qRT-PCR was quantified as 
follows: 2-CT = CT gene of interest – CT gapdh [88]. 
 Electric cell-substrate impedance sensing 5.7
Resistance measurements were performed using an ECIS ZӨ apparatus (Applied 
Biopyhysics Inc.,Troy, NY) and either 8W1E arrays (Fig.20) or 8W10E+ arrays (Fig. 
18, 21) both consisting of 8-wells with an area of 0.8 cm2/well each and 1 or 40 gold 
electrodes with a diameter of 250 μm, respectively (Applied Biopyhysics Inc., Troy, 
NY). Before seeding cells, each well was preincubated with serum-free DMEM 
overnight followed by a 20 minutes coating with 0.1% gelatine gold (Carl Roth GmbH, 
Karlsruhe, Germany) and 0.9% sodium chloride in PBS, followed by 3 wash steps 
with serum free DMEM. 17 hours post transfection cells seeded into 8W1E and 
8W10E+ plates, respectively. The arrays in the measurement station were then 
placed in an incubator (37°C, 5% CO2). Total resistance was measured in real-time 
at a frequency of 4 kHz. The complex impedance spectrum (Z, R, C) for each well 
was measured by applying an AC signal to the cells on the gold electrode, which 
output is measured over a frequency spectrum from 62.5 Hz to 64 kHz every 180 
seconds by a second counter electrode. From this data the 2 [ ×cm2] value and Rb 
[×cm2] was calculated using ECIS software (Applied Biopyhysics Inc.Troy, NY). 
 Cloning 5.8
Full length Pim1 was inserted into pCMV-Tag 2A by restriction enzyme digest from 
pdsRED with EcorI/SalI. The Pim1 truncation constructs were amplified from a 
pdsRED C1-Pim1 vector with specific primers, containing the restriction sites 
BglII/SalI and  subcloned into pCMV-Tag 2A and pdsRED C1 vector system (for 
details see section 8.5). pPCR amplifications were performed using the PfuTurbo® 
DNA-polymerase (Stratagene, La Jolla, CA). The primers are listed in the primer 
table (supplementary material table S2, section 12).   
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 Proliferation assay 5.9
4×103 MAEC/well were plated in 96-well cell culture dishes (TPP, Trasadingen, 
Switzerland) o/n. Cells were washed three times with PBS and 24 hours starved in 
DMEM without FCS. Then rapamycin or diluent was added for 1 hour and 
subsequently FCS was added to the cells cultures in a final dilution of 10%. Proliferation 
was measured with the metabolic indicator Alamar blue (Invitrogen, Carlsbad, CA), 
which was added at 24–48 h after rapamycin treatment. The degree of proliferation 
was determined using SpectraMax microplate reader (Molecular Devices, Sunnyvale, 
CA), applying an excitation wavelength from 530nM and an emission wavelength of 
590nm. Control wells contained DMEM with appropiate rapamycin concentrations to 
provide a background level measurement. 
 Kinase inhibitors and extraction of cytosolic and nuclear fractions 5.10
To inhibit protein kinases of different signalling pathways, the cells were seeded and 
grown overnight, as described in cell culture methods. Afterwards the cells were 
washed three times with PBS and 24 hours starved in DMEM without FCS. Then the 
appropriate inhibitor or diluent was added for 1 hour and subsequently FCS was 
added to the cells cultures in a final dilution of 10%. After 3 hours the cells were 
harvested and cytosolic and nuclear fractionation was performed with a NE-PER 
nuclear and cytoplasmic extraction kit (Thermo Scientific, Waltham, MA), according 
to the manufacturers protocol.  
 
Inhibitor Target protein Abbreviation Concentration 
Akt inhibitor IV AKT/Protein kinase B AKT 1M 
Gö6983 Protein kinase C α,,,, PKC 1M 
U0126 
Mitogen-activated protein kinase 
1/2 
MEK 5M 
GSK3IX Glycogen synthase kinase-3 / GSK 1M 
Rapamycin Mammalian target of rapamycin RPM 0. 
LY294002 PI3Kinase LY 5M 
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Table 1. List of the different kinase inhibitors with their corresponding target and the final 
concentration used.  
 FACS analysis 5.11
The apoptosis assay was performed using a Fluoresceinisothiocyanat (FITC) 
Annexin V/Dead cell apoptosis kit (Invitrogen, Carlsbad, Ca).  Therefor the cells were 
harvested and washed in cold PBS. After centrifugation the cells were resuspended 
in 1X annexin-binding buffer to a density of ~1×106 cells/mL. According to the 
protocol 5l of FITC Annexin V and 1l of the 100g/mL Propidium iodide (PI) 
working solution were added to each 100l of cell suspension. After 15min incubation 
at room temperature, 400l of 1X annexin-binding buffer was added to each sample 
and the tubes were kept on ice until sorting. The samples were then analyzed with a 
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) at emission wave lengths of 
530nm and >575nm.     
 Statistical analysis 5.12
All statistical tests were performed using GraphPad Prism 5.04 for Windows 
(GraphPad software, San Diego, CA). For analysis of repeated measurements a two 
way Anova followed by a Bonferroni post test was performed. Differences between 
two groups were evaluated using unpaired t-test. To compare more than two groups 
one way anova followed by a Bonferroni post test was done. a.u.c. was calculated 
over indicated time periods using GraphPad software. Data are represented as 
means ± s.e.m.  
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6 RATIONALE AND AIMS OF THE 1ST PART OF THE THESIS  
In the past years many studies on rapamycin and its effect in cancer therapy have 
been performed. However, the inhibitory effects on tumor growth remain restricted to 
specific cancer subtypes and have not a generally extended efficacy. This drug 
resistance can be caused by redundant signalling pathways. In the past, several 
proteins have been identified, which counteract rapamycin-induced growth arrest . 
Therefore, these molecules may serve as targets for combined drug therapy, to 
improve the efficacy of anti-cancer treatments. PIM kinases have been shown to 
substitute for mTOR-mediated signalling. Combination of PIM1 kinase inhibitors and 
rapamycin may have a beneficial effect on regression of tumors. Nevertheless, tumor 
growth depends highly on vessel infiltration into the malignant tissue. Therefore, in 
addition to blocking cancer cell growth, inhibition of tumor angiogenesis may be of 
relevance. PIM1 has been described in various human tumors. Yet little is known 
about the function of PIM1 in relation to mTOR signalling on endothelial cells.  
 
One goal of my thesis was: 
 
- To explore whether abrogation of PIM1 improves known growth inhibitory 
effects of rapamycin on endothelial cells and if so…  
 
- To investigate the mechanisms by which PIM1 antagonizes the 
antiproliferative properties of rapamycin. 
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7 RESULTS PART I :  
PIM1 nuclear translocation confers rapamycin insensitivity in 
endothelial cells and promotes cell proliferation 
 Pim1 deletion enhances the inhibitory effect of rapamycin on cell 7.1
proliferation.  
T-cells deficient for Pim1 and Pim2 displayed an unexpected sensitivity to rapamycin. 
The cellular response to rapamycin was not only restricted to a decrease in survival, 
but also to complete abrogation of proliferation [83]. Based on this observation we 
investigated whether Pim1 deletion similarly affects the proliferative response in 
endothelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Cell proliferation and apoptosis of wildtype vs. Pim1-/- endothelial cells. (A)
Fold decrease cell proliferation of wildtype compared to Pim1-/- MAEC treated with 250nM
rapamycin (RPM) and control. (B) FACS analysis of corresponding treatment conditions of
wildtype vs. Pim1-/- cells. Wildtype cells (black bars), Pim1-/- cells (white bars). Data are
represented as means ± s.e.m. (n=3). *P<0.05, **P<0.01 
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Wildtype and Pim1-/- endothelial cells were treated for 24 hours with and without 
rapamycin (RPM). Proliferation, viability and apoptosis were quantified (Fig. 10). 
Pim1 knockout decreased proliferation by 28 ± 0.1% compared to wildtype cells (Fig. 
10A left side). Pim1 knockout MAEC treated with rapamycin reduced proliferation by 
63 ± 0.1% in comparison to wildtype cells (Fig. 10A right side). Thus, we found a 1.3-
fold and a 3.2-fold decrease in proliferation after rapamycin treatment in wildtype and 
knockout cells, respectively. To exclude a possible toxic effect of rapamycin resulting 
in reduced cell numbers due to apoptosis, we analyzed cell viability by FACS 
analysis (Fig. 10B). Wildtype and Pim1-/- cells grown under the same conditions were 
sorted by FACS. We observed no decrease in the percentage of viable wildtype or 
Pim1-/- cells after rapamycin treatment (Fig. 10B left panel). Under all conditions more 
than 90% cells were viable. Accordingly, no significant increase of the apoptotic cell 
population was observed, comparing wildtype and Pim1-/- cells treated with 
rapamycin and controls (Fig. 10B right panel). In all conditions tested the percentage 
of apoptotic cells was less than 2%. Taken together, these data suggest, that Pim1 
knockout in endothelial cells increases sensitivity to rapamycin.   
 mTOR and Akt inhibition increases PIM1 protein expression.  7.2
To investigate whether mTOR inhibition by rapamycin and subsequent changes in 
cell proliferation specifically affect PIM1 protein levels, we treated wildtype MAECs 
with protein kinase inhibitors blocking different signaling cascades (Table 2).  
 
Inhibitor Target protein Abbreviation 
Akt inhibitor IV AKT/Protein kinase B Akt 
Gö6983 Protein kinase C α,,,, PKC 
U0126 Mitogen-activated protein kinase 1/2 MEK 
GSK3IX Glycogen synthase kinase-3 / GSK 
Rapamycin Mammalian target of rapamycin RPM 
LY294002 PI3Kinase LY 
 
Table 2. Compounds used to inhibit different signalling cascades. 
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We furthermore differentiated between cytosolic and nuclear PIM1 localization (Fig. 
11), since subcellular localization of PIM1 was reported to be associated with specific 
PIM1 function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Akt and rapamycin inhibition increases PIM1 expression levels. (A) PIM1
expression levels of cytosolic and nuclear fractions from MAEC treated with inhibitors of
different signaling cascades (left panel). Corresponding densitometric quantification of PIM1
expression levels. (right panel) (B) Immunofluorescence image of endogenous PIM1 after 3
hours of rapamycin treatment (lower panel) and control (upper panel). Endogenous PIM1
(left panel), nuclei (middle panel) and merge (right panel). In the merge picture the nuclei are
displayed in blue and PIM1 kinase in yellow. (n=3). *P<0.05, **P<0.01 
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PIM1 protein expression levels from cytosolic and nuclear fractions were quantified 
after 3 hours of treatment with the inhibitors. We found that mTOR and AKT inhibition 
significantly increased PIM1 expression both in cytosolic and nuclear fractions with 
no significant alterations in subcellular distribution (Fig. 11A). PIM1 was upregulated 
3.9 fold after AKT inhibition and 4.2 fold after mTOR inhibition by rapamycin in the 
cytosolic fractions. It was upregulated 4.7 and 5.2 fold, respectively, in nuclear 
fractions. We observed an upregulation of PIM1 in the cytoplasm and the nucleus 
after 3 hours of rapamycin treatment, as visualized by immunofluorescence analysis 
(Fig. 11B). 
Thus, rapamycin inhibited proliferation of endothelial cells lacking PIM1 more 
effectively. On the other hand, rapamycin increased PIM1 protein expression, both 
within the cytosol and nucleus. Based on these data, we formulated the hypothesis, 
that PIM1 may exert a function in the nucleus that counteracts or partially rescues 
decrease in proliferation in response to inhibition by mTOR.  
To test this hypothesis, we constructed a vector-based Pim1 expression system with 
PIM1 mutations that localize exclusively to the nucleus.  
 Generation of Pim1 expression systems 7.3
7.3.1 Generation of a dsRED-Pim1 expression system 
To re-express Pim1 in MAEC, we generated a dsRED-Pim1 expression vector. Pim1 
cDNA was cloned into a pdsRED C1 expression vector (Fig. 12A lower panel). The 
tag was N-terminally linked to Pim1 cDNA (Fig. 12A upper panel). dsRED-Pim1 was 
then transfected into Pim1-/- MAEC and the transfection efficiency was assessed by 
immunofluorescence microscopy and counted as 50-60% (data not shown). Fig. 12B 
shows a single aortic endothelial cell expressing dsRED-PIM1.  
 
 
 
 
 
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2 Generation of a FLAG-Pim1 expression system 
We generated a second expression system with a low molecular weight tag. To do 
so, Pim1 cDNA was cloned into a pCMV-Tag 2A expression vector (Fig.13A lower 
panel).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. dsRED-Pim1 expression system. (A) Schematic representation of the Pim1
cDNA (upper panel) inserted in a pdsRED C1 expression vector (lower left panel). (B) Pim1-/-
MAEC expressing dsRED-Pim1 (red). MCS: multiple cloning site (yellow).  
Figure 13. FLAG-Pim1 expression system. (A) Schematic representation of the Pim1 cDNA 
(upper panel) inserted in a pCMV-Tag 2A (lower left panel) expression vector. (B) Whole cell 
lysate of Pim1-/- MAEC expressing FLAG-Pim1. MCS: multiple cloning site.  
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As with the pdsRED-Pim1 vector, the FLAG-tag was N-terminally linked to Pim1 
cDNA (Fig.13A upper panel). FLAG-Pim1 was then re-expressed in Pim1-/- MAEC 
and protein expression levels assessed by Western blot (Fig.13B). 
7.3.3 Generation of a FLAG-Pim1/dsRED-Pim1 carboxy-terminal truncations 
PIM1 nuclear localization has been proposed to depend on half of its carboxy 
terminus (C-terminus) [89]. Our in silico analysis using the open access NucPred 
software (www.sbc.su.se/~maccallr/nucpred) revealed no nuclear localization signal 
(data not shown). mTOR has been shown to regulate cytoplasmic/nuclear shuttling of 
Nuclear factor of activated T-cells cytoplasmic 4 (NFATc4) by phosphorylation [90]. 
We therefore tested whether a similar mechanism could influence the increase of 
PIM1 nuclear localization. To identify critical phosphorylation sites, i.e., minimal 
critical C-terminal truncations responsible for PIM1 nuclear localization we generated 
dsRED-Pim1 and FLAG-Pim1 carboxy-terminal mutations with truncation at potential 
mTOR-phosphorylation sites. As shown in Fig. 14, Pim1 cDNA was truncated at the 
first seven putative phosphorylation sites: Ser312, Ser308, Ser306, Ser276, Ser261, 
Ser260, Ser227 (Serine).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. C-terminal truncation sites of PIM1 kinase. Schematical representation of
PIM1 kinase with the serines of interest shown in orange (upper part). Scheme how the C-
terminal primers bind to the leading strand (lower part). S: Serine (orange), Stop: Stop codon
(green), Sal I: restriction site (red), N-terminus: Amino-terminus, C-terminus: carboxy-
terminus. 
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Therefore, Pim1 cDNA was amplified, with primers containing the appropriate 
restriction sites for insertion into pdsRED C1 or pCMV-Tag 2A expression vector at 
5’- and 3’-ends. While the amino-terminal primer remained the same for each 
reaction, the carboxy-terminal primers were designed to bind beyond the appropriate 
serine followed by a stop codon each (Fig. 14).  
 Truncation of C-terminal residues of dsRED-Pim1 beyond Serine 276 7.4
(Pim1Δ276-313) results in an increased number of PIM1 nuclear positive 
cells. 
Full length dsRED-Pim1 (Pim1wt) treated with or without rapamycin and dsRED-Pim1 
truncation mutants (Pim1 were re-expressed in Pim1-/- MAEC. Cells positive 
for nuclear PIM1 protein were quantified by immunofluorescence microscopy 
(Fig.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell cultures of MAEC expressing PIM1wt, treated for 3 hours with rapamycin, 
displayed a 1.88-fold increase in nuclear PIM1 compared to untreated cells. MAEC 
Figure 15. Percentage of nuclear PIM1 positive Pim1-/- cell cultures, transfected with
dsRED-Pim1 wildtype (black bar), dsRED-Pim1 wildtype with RPM (open bar) and c-
terminal truncation mutants Pim1313-227 (spotted bar). Data are represented as means ±
s.e.m. (n=3). **P<0.05, ***P<0.005, #P<0.0001. 
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transfected with Pim1Pim1and Pim1showed no significant 
increase in nuclear PIM1 positive cells. However, except for MAEC transfected with 
truncation mutant Pim1c-terminal truncations beyond Serine 276, displayed a 
significantly higher percentage of PIM1 nuclear positive cells: Pim1 2.9 fold,  
Pim12.2 fold and Pim13.2-fold compared to Pim1wt transfected cells. 
 Truncation of C-terminal residues of FLAG-Pim1 beyond Serine 276 7.5
(Pim1Δ276-313) results in nuclear localization of the kinase and an increases 
MAEC proliferation.  
The same experiment was also performed  with the FLAG-Pim1 constructs that were 
re-expressed in Pim1-/- cells (Fig.16A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. FLAG-Pim1276-313 localizes to the nucleus. (A) Scheme of the two truncations
constructs, FLAG-Pim1wt and FLAG-Pim1276-313 transfected into Pim1-/- MAEC. (B) MAEC
transfected with FLAG-Pim1wt (upper panel) and FLAG-Pim1276-313 (lower panel) cDNA.
FLAG-Pim1 (left panel), nuclei (middle panel) and merge (right panel). In the merge picture
the nuclei are displayed in blue and PIM1 kinase in yellow. (C) Proliferation measurement of
Pim1-/- MAEC re-expressing FLAG-Pim1wt and FLAG-Pim1Δ276-313. Data are represented as
means ± s.e.m. (n=3). *P<0.005.	
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Fluorescence microscopy using anti-FLAG antibodies revealed that only Pim1 
truncations beyond serine 276 resulted in nuclear translocations, whereas smaller 
truncations retained an even distribution of PIM1 in the cytosol (Fig.16B). In order to 
investigate whether phosphorylation of the sites around and at serine 276 is critical 
for nuclear localization, we generated Serine-phosphorylation and Serine-
dephosphorylation mimicking mutants. This was performed by site directed 
mutagenesis of the serines 276, 261 and 306 into either an Alanine (Ala) or a 
Glutamate (Glu). Re-expression of these phosphorylation mimicking mutants in Pim1-
/- cells revealed an inconsistent picture, which did not enable us to pinpoint one 
specific Serine residue to be responsible for nuclear translocation (data not shown). 
We therefore continued with the FLAG-Pim1Δ276-313 truncation mutant that was 
consistently found in the nucleus to perform proliferation experiments. FLAG-Pim1wt 
and FLAG-Pim1Δ276-313 were overexpressed in Pim1-/- cells and cell proliferation was 
assessed (Fig.16C). Interestingly Pim1-/- MAEC expressing FLAG- Pim1Δ276-313 
displayed a 1.94 fold higher proliferation than cells expressing full length FLAG-Pim1. 
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8 RATIONALE AND AIMS OF THE 2ND PART OF THE THESIS 
Elevated Pim1 mRNA and protein levels correlate with the metastatic potential of 
tumors by facilitating migration and anti-adhesion [73-75]. Vice versa, inhibition of 
PIM1 kinase activity diminishes cancer cell migration and invasion in vitro [10, 75].  
Endothelial cells play a pivotal role in these processes by contributing a barrier to the 
blood stream. PIM1 has been shown to be expressed in endothelial cells during in 
vivo angiogenesis and to be sensitive to VEGF in vitro [66]. In solid tumors, a 
prerequisite for cancer cell extravasation is alteration of endothelial cell barrier 
function, known to be associated with changes in expression of molecules important 
for endothelial cell adhesion [39, 91, 92]. However, so far no studies in endothelial 
cells exist, analyzing PIM1 function in endothelial barrier function. Here we 
investigated whether PIM1 regulates MAEC monolayer integrity. 
 
Specifically my goals were: 
 
- To functionally characterize adhesion properties of MAEC with deleted or 
inactivated PIM1 kinase. 
- To determine the molecules which are differentially expressed in the adhesive 
phenotype of Pim1-/- MAEC.   
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9 RESULTS PART II :  
Pim1 knockout imposes a superadhesive phenotype on endothelial 
cells 
 Pim1 kinase deletion and inhibition slows endothelial cell detachment by 9.1
trypsinization and  increases cell adhesion. 
To investigate whether PIM1 influences endothelial cell adhesion characteristics we 
started with assessing resistance of electric current across endothelial monolayers 
(electric cell impedance sensing (ECIS)) and trypsin-mediated cell detachment after 
PIM1 kinase inhibitor treatment. Confluent wildtype MAECs were treated with the 
imidazo[1,2-b]pyridazine compound K00486, a kinase inhibitor reported to inhibit 
human PIM1 kinase activity in vitro [93]. The resistance of the cell monolayer was 
recorded for 24 hours at a frequency of 4kHz using ECIS (Fig. 18A). Compared to 
control, we observed a significant increase of 80 ± 5 ohm of total resistance at 4kHz 
in cells treated with K00486, indicating the formation of a tighter cell monolayer.  
In parallel, MAECs were trypsinized 24 hours after seeding, and the detachment 
process was followed in a time course (Fig. 18B): A significant delay in the 
detachment of inhibitor-treated versus untreated cells was observed as early as after 
2 min (9±0.002% vs. 23±0.01% of detached cells in the supernatant) of trypsinization. 
The difference in detachment remained significant also for later time points (n=3, 
P<0.0001). Even though the PIM1 inhibitor K00486 has been suggested to inhibit 
only PIM1 kinase [93] we could not exclude unspecific inhibition by this compound. 
To further substantiate our findings of increased endothelial cell adhesion after PIM1 
inhibition, we isolated MAECs from mice deficient for PIM1 [64] and corresponding 
control mice. Pim1 mRNA and protein expression in the isolated cells was assessed 
using quantitative real-time PCR (qRT-PCR) (Fig. 18C) and Western blotting (Fig. 
18D) confirming the knockout of Pim1. Trypsin treatment of these cells for 0, 1, 2, 3, 
4 and 5 minutes displayed a marked resistance to trypsinization and detachment of 
endothelial cells lacking PIM1. After 3 minutes, only 5±1% Pim1-/- cells were 
detached compared to 36±3% of wildtype cells (n=3, P<0.001). Similarly, after 5  
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Figure 18. Detachment of wildtype and Pim1-/- endothelial cells after trypsinization. (A)
Time course of total resistance at 4 kHz of endothelial control and cells treated with K00486
over a period of 24 hours using ECIS. (B) Time course displaying number of cells detached
represented as percentage of total adherent cells; control vs. cells treated with K00486. (C)
Steady state mRNA expression levels of wildtype and Pim1-/- cells. (D) Corresponding
Western blot of wildtype and Pim1-/- cells. (E) Time course displaying number of cells
detached represented as percentage of total adherent cells; wildtype vs. Pim1-/-cells. (F)
Representative micrographs of wildtype and Pim1-/- cells before and after 3 and 5 minutes of
trypsin treatment. -actin was used as loading control. Black symbols indicate wildtype, grey
wildtype with K00486 and open Pim1-/- cells. Data are represented as means ± s.e.m. (n=3).
*P<0.05, #P<0.0001. 
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minutes, Pim1-/- MAECs number in the supernatant was significantly lower (n=3, 
P<0.001) (Fig. 18E), which is also visible in corresponding micrographs (Fig. 18F).  
 Pim1-/- decreases cell migration in a wound healing assay.  9.2
The differences in cell adhesion properties suggested that the migratory response of 
Pim1-/- cells might be also affected. We therefore investigated cell motility (Fig. 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Wound healing assay comparing wildtype and Pim1-/- MAEC. (A)
Micrographs from wildtype (upper panel) and Pim1-/- (lower panel) cells 0, 8 and 24 hours
after wounding. (B) Corresponding time course displaying the percentage of recolonized
wound after 0, 4, 8 and 24 hours of cell migration. Black symbols indicate wildtype and
open Pim1-/- cells. Data are represented as means ± s.e.m. (n=5). #P<0.0001 
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Confluent wildtype and Pim1-/- endothelial monolayers were scratched and cell 
reinvasion into the wound was recorded over 24 hours. Quantification of the light 
micrographic pictures (Fig. 19A) revealed a 28.1±1.3% lower migration rate for Pim1-
/- cells (Fig. 19B).  
 Pim1-/- MAECs form tighter cell-substratum and cell-cell contacts. 9.3
Adhesion properties of wildtype and Pim1-/- cells were further analyzed using ECIS. 
Cells were seeded at confluence, and total resistance of cell layers was measured 
during 24 hours at a frequency of 4kHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Real-time monitoring of adhesion process and monolayer formation in wildtype and
Pim1-/- MAECs. (A) Time course of total resistance at 4 kHz of endothelial wildtype and
Pim1-/- endothelial cells over a period of 24 hours using ECIS. (B) Schematic view of an
ECIS plate coated with cells. Rtot: total resistance (cell occupancy); Rb: resistance between
the cells; α2: cleft impedance parameter; (C) 2 value and Rb value measurement of  the
confluent cell layers from 8 to 24 hours. Wildtype (filled symbols) and Pim1-/- (open symbols).
Bars represent the area under the curve (a.u.c.) from 8 to 24 hours as means ± s.e.m. (n=3).
**P<0.001, #P<0.0001. 
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After 8 hours the cells formed a confluent monolayer at the resistance value of 5600 
± 200 ohm for wildtype and 7800 ± 200 ohm for Pim1-/- cells (n=3, P<0.0001, Fig. 
19A).  
The ECIS model allows to differentiate between tightness of cell-cell contacts (Rb) 
and the strength of the cell-substratum adhesion (2) (Fig. 20B) [94, 95]. Area under 
the curve (a.u.c.) analysis for these parameters from 8 to 24 hours indicated a 
significant 2.3-fold of Rb (n=3, P<0.0001) and a 1.5-fold increase (n=3, P<0.0003) of 
2 respectively, in Pim1-/- cells (n=5, P<0.001) (Fig. 20C). Thus, Pim1 deletion in 
endothelial cells markedly and significantly strengthens cell-cell and cell-substratum 
adhesion as judged from the Rb and 2 value. 
 Expression of PIM1 leads to a decrease in total resistance of endothelial 9.4
Pim1-/- cells.  
To assess whether the hyper-adhesive properties of Pim1-/- cells might be indeed a 
consequence of loss of PIM1, we aimed to restore the phenotype by reintroduction of 
FLAG-Pim1 cDNA into knockout cells. The amount of re-expressed FLAG-Pim1 was 
determined by qRT-PCR and adjusted to similar levels of endogenous Pim1 mRNA 
(Fig. 21A).  
We measured the total resistance of Pim1-/- cells expressing FLAG-Pim1 cDNA, 
wildtype and Pim1-/- cells transfected with control plasmid during 24 hours. 
Attachment and plateau establishment were not significantly changed in Pim1-/- and 
Pim1-/- cells after FLAG-Pim1 cDNA expression. However, after 16 hours of 
measurement the electrical resistance of cells expressing FLAG-Pim1 significantly 
decreased compared to Pim1-/- cells. After 24 hours the rescue effect in Pim1-/- cells 
expressing FLAG-Pim1 reached a maximum of approximately 40% reduction to 
wildtype resistance values (Fig. 21B).  
Area under the curve analysis for the strength of cell-substratum adhesion and 
tightness of cell-cell contacts from 8 to 24 hours was calculated for wildtype, Pim1-/- 
and Pim1-/- cells expressing FLAG-Pim1. Reintroduction of FLAG-Pim1 into wildtype 
or Pim1-/- cells did not affect 2-value (Fig. 21C). However, the difference in the area 
under the curve (a.u.c.) for Rb between wildtype and Pim1-/- cells was reduced by  
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54% (n=3, P<0.001) when re-expressing FLAG-Pim1 in Pim1-/- cells (Fig. 21D) Thus, 
reintroduction of Pim1 cDNA into Pim1-/- MAEC restores Rb values to more than half 
of that of Rb wildtype levels.  
Figure 21. ECIS analysis of Pim1-/- cells after FLAG-Pim1 cDNA re-expression. (A)
qRT-PCR of endogenous Pim1 from wildtype and Pim1-/- cells and Pim1-/- cells transiently 
transfected with FLAG-Pim1 cDNA, quantified with primers amplifying the FLAG sequence.
(B) Determination of total resistance at 4 kHz during 24 hours from wildtype, Pim1-/- and 
FLAG-Pim1 expressing Pim1-/- cells. (C) Area under the curve analysis of 2 value from 8 to 
24 hours of wildtype, Pim1-/- cells and Pim1-/- cells transfected with FLAG-Pim1 cDNA. (D)
Area under the curve analysis of Rb from 8 to 24 hours of wildtype, Pim1-/- cells and Pim1-/-
cells transfected with FLAG-Pim1 cDNA (left panel) with the corresponding resistance value
curves (right panel). Resistance values were normalized to value 1 at time point 0 hours.
Arbitrary units (a.u.) wildtype (black), Pim1-/- (red), Pim1-/- transfected with FLAG-Pim1 (blue). 
Data are represented as means ± s.e.m. (n=3). **P<0.001. 
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 Endothelial cell-cell junctions and focal adhesion structures are more 9.5
pronounced in Pim1 knockout cells. 
-catenin is a protein of the adherens junction complex and vinculin is an ubiquitary 
expressed protein involved in focal adhesion and also cell-cell contact formation [96, 
97].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Vinculin and -catenin protein expression analysis. (A) Vinculin
immunofluorescence images of MAEC, wildtype (upper left panel) vs. Pim1-/- (lower left
panel) and F-actin staining of the corresponding area (middle panel). Merge of vinculin (red)
and F-actin (green) images (left panel). (B) β-catenin (red) immunofluorescence images of
wildtype (upper panel) and Pim1-/- (lower panel) MAEC. On the right a corresponding 10
times magnification of the area is indicated by a white rectangle. (C) Western blot of vinculin
(upper panel) and β-catenin (lower panel) from wildtype and Pim1-/- whole cell lysates. The
nuclei are shown in blue. White arrows indicate the overlapping regions (yellow) (Total
magnification ×100).  
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To validate the increased resistance in cell adherens junctions and focal adhesions 
observed by ECIS, we assessed the protein expression levels of -catenin and 
vinculin by immunofluorescence imaging and Western blot (Fig. 22). Fluorescence 
imaging disclosed a much more prominent vinculin patterning in Pim1-/- cells: The 
knockout cells formed more vinculin clusters around the cell (white arrows) (Fig. 22A 
left panel). Additionally also F-actin, which is bound by vinculin, was stained (Fig. 22A 
middle panel). The overlay of vinculin and actin stainings visualizes the difference in 
the amount of focal adhesion clusters (Fig. 22A right panel).  
To investigate whether we also may find distinct changes in adherens junctions we 
stained for -catenin in wildtype and knockout cells (Fig. 22B left panel). Indeed the 
-catenin clusters were expanded in Pim1-/- cells, which is also visualized in a 10-
times magnification in Fig. 22B right panel. Nevertheless, we found no changes in 
overall protein expression of -catenin and vinculin when comparing wildtype and 
Pim1-/- cells (Fig.22C).  
 Gene expression analysis reveals importance of PIM1 in cell adhesion and 9.6
cytoskeleton remodeling. 
To obtain a more global view of the capacity of PIM1 to regulate cell adhesion we 
compared mRNA expression of wildtype and Pim1-/- cells using a two color Agilent 
DNA microarray. 
Analysis of the gene expression data revealed 1598 significantly regulated genes 
(P<0.01) from which 61% were up- and 39% downregulated. The most regulated 
genes include Foxg1 with a ratio of 200-fold upregulation and Eif2s3 with a 70-fold 
downregulation (Table 3).  
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Single genes were summarized by their biological function using MetaCore™ 
analysis. Intriguingly, four out of ten most significantly regulated biological processes 
were computed as cell adhesion, migration and cytoskeleton remodeling (Table 4). 
This assignment is in line with our cell biological assessment.   
 
 
 
 
 
Table 3. Expression of differently expressed genes in Pim1-/- MAECs as identified by 
microarray analysis. 
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A specific gene set involved in cell adhesion was selected for further validation (Table 
5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Involvement of differently regulated genes in biological processes comparing
Pim1-/- versus wildtype cells as analysed by GeneGo software (top down by P-value). 
Table 5. Genes involved in cell adhesion up- or downregulated in Pim1-/- cells. A cluster
of genes which were found to be significantly regulated in the gene expression analysis was
selected for further validation by qRT-PCR. (top down by ratio; P<0.05; †>0.05).  
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7 out of these 12 genes could be validated using qRT-PCR: the integrin family 
member integrin alpha 7 (Itga7), the junctional adhesion molecule 2 (Jam2), T-
cadherin also known as cadherin 13 (Cdh13), a disintegrin and metalloproteinase 
domain-containing protein 23 (Adam23),  the extracellular matrix proteins collagen  
type VI, alpha 3 (Col6a3), collagen type XI, alpha 1 (Col11a1) and sushi, von 
Willebrand factor type A, epidermal growth factor and pentraxin domain containing 1 
(Svep1) which belongs to a new group of membrane proteins involved in cell 
adhesion [98]. The most significantly regulated genes also displaying the highest 
mRNA expression levels in Pim1-/- cells were identified as Col6a3 (fold induction = 
51.6; P<0.0001), and Cdh13 (fold induction = 81.9; P<0.0002) (Fig. 23A), both 
upregulated in Pim1-/- cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Validation of the adhesion cluster using qRT-PCR. (A) mRNA from wildtype 
and Pim1-/- MAECs was isolated after 24 hours and steady state expression levels of
indicated genes were validated by qRT-PCR. (B) Western blot of CDH13 and COL6A3 from 
wildtype and Pim1-/- whole cell lysates. Data are represented as means ± s.e.m. (n=3).
*P<0.05, **P<0.001, #P<0.0001. 
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Figure 23B shows protein expression levels of CDH13 and COL6A3, proteins 
involved in cell-cell and cell substratum adhesion, respectively.  
 Pim1-/--deposited matrix induces adhesion characteristics of Pim1-/- cells 9.7
in wildtype cells  
Extracellular matrix deposition and composition is of fundamental importance in cell 
adhesion and migration [99]. We found significantly different gene expression of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Pim1-/- but not wildtype MAEC display deposits of COL6A3-positive fibre-like
structures outside cells. (A) Representative micrographs of COL6A3 (red) and nuclear
(blue) immunestaining in confluent wildtype (left) and Pim1-/- (right) MAEC (n=3, magnification
100x). (B) Representative micrographs of COL6A3 (red) and nuclear (blue) immunestaining
in subconfluent wildtype (left) and Pim1-/- (right) MAEC (n=3, magnification 63x). (C) Confocal
image of a COL6A3 (green) immunestaining from Pim1-/- MAEC. Nuclei are shown in red.
(magnification 100x).   
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matrix components and cell-matrix receptors, such as collagens and integrins. 
COL6A3 as the most strongly and significantly expressed matrix component was 
further examined by immunostaining. We found that confluent Pim1-/- but not wildtype 
MAEC expressed COL6A3 positive bundles inside the cells, extending in network-like 
structures on top of endothelial cells (Fig 24A, right micrograph). Furthermore, Pim1-/- 
but not wildtype MAEC deposited fibre-like structures containing COL6A3 between 
cells accumulating on the cell-free culture plate surface (Fig24B, right micrograph). 
Figure 24C shows a magnification of a COL6a3 immunostaining from Pim1-/- cells.  
We therefore aimed at determining whether the adhesion properties of Pim1-/- cells 
also depend on this specific ECM deposition. Wildtype cells were cultivated on ECM 
deposited by wildtype or Pim1-/-  cells (Fig. 25A).  
Trypsin treatment of these confluent cells for 0, 1, 2 and 3 minutes displayed a 
marked delay of the detachment of wildtype endothelial cells cultured on matrix 
deposited by Pim1-/- cells (Fig. 25A). Wildtype cells remained attached to the Pim1-/- 
matrix to 84±1% in contrast to 52±8%  on the wildtype matrix after 1 minute of trypsin 
treatment and three PBS washing steps (n=3, P<0.003). After three minutes and 
three PBS washing steps 63.2±13% of wildtype cells remained attached to the Pim1-/- 
matrix whereas only 16.8±12% of wildtype cells remained attached to the wildtype 
matrix (n=3, P<0.02).  
To compare the degree to which Pim1-/- deposited matrix was able to induce 
adhesion characteristics of Pim1-/- cells in wildtype cells, we performed trypsinization 
experiments with confluent wildtype and Pim1-/- cells which were washed three times 
after three minutes of trypsin treatment. Again, supernatant was collected and cells 
counted. The washing steps decreased the number of wildtype MAEC remaining 
attached to the culture dish (21.7±1.8%), whereas Pim1-/- cells still resisted 
trypsinization (77.5±0.9%, n=5, P<0.0003) (Fig. 25B). The percentage of Pim1-/- cells 
remaining attached to the substratum was similar and statistically not different 
compared to the percentage of wildtype cells remaining attached to the Pim1-/- 
deposited matrix after three minutes of trypsin treatment (P=0.47>0.05, n=3) (Fig. 
25B). Finally, we investigated, whether Pim1-/- cell-deposited matrix was sufficient to 
induce structural changes in adherens junctions of wildtype MAEC as observed in 
Pim1-/- cells (see Figure 22B). Indeed, when cultivating wildtype MAEC on Pim1-/- 
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cell-deposited matrix and staining confluent cultures, we observed enhanced -
catenin containing structures at cell-cell borders (Figure 25C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Detachment of wildtype cells grown on wildtype or Pim1-/- ECM compared to
wildtype and Pim1-/- cells after trypsinization. (A) Time course represented as a
percentage of adherent wildtype cells after 0, 1, 2 and 3 minutes of trypsin treatment, grown
either on wildtype or Pim1-/- ECM. Wildtype cells grown on wildtype ECM are shown as black
symbols and wildtype cells grown on Pim1-/- ECM as open symbols. (B) Corresponding graph
after 3 minutes of trypsinization compared to wildtype and Pim1-/- cells grown on their intrinsic
ECM. Wildtype cells are shown as black, knockout cells as white bars, wildtype cells on
wildtype ECM as black bars with a black diamond and wildtype cells on knockout ECM as
black bars with an open circle. (C) Immunofluorescent staining of -catenin (red) and nuclei
(DAPI, blue) of wildtype MAEC cultured on matrices deposited by wildtype MAEC
(micrograph on the left) and by Pim1-/- MAEC (micrograph on the right; magnification 63x,
n=3).Data are represented as means ± s.e.m. (n=3). *P<0.05, **P<0.001, #P<0.0001. 
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Thus, ECM deposited by Pim1-/- cells is sufficient to mediate a hyperadhesive 
phenotype similar to that of Pim1-/- cells with respect to cell detachment and 
adherens junction strengthening.  
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10 DISCUSSION 
In healthy conditions PIM1 kinase expression is low and no major phenotypes have 
been found in Pim1-/- animals so far [64]. However animals deficient for all three PIM 
kinases show reduced body size at birth and in vitro response of hematopoietic cell 
populations to growth factors was impaired [1]. PIM1 overexpression has been 
implicated in different types of cancer where it enhances cell proliferation and 
metastasis [75, 100]. In line with this, inhibition of PIM1 kinase activity diminishes 
cancer cell migration and invasion [10, 75]. Tumor progression and tumor cell 
extravasation not only depend on cancer cells. Angiogenesis and blood vessel 
permeability, i.e. endothelial monolayer integrity, are also critical determinants for 
cancer progression [9]. However, little is known about primary endothelial cell 
cultures and the impact of PIM1 kinase on endothelial barrier integrity. 
Vessel growth is stimulated by proangiogenic factors and depends on cell 
proliferation and migration. Cell proliferation needs activation of specific signalling 
pathways involved in cell cycle progression. Rapamycin is a potent anti-proliferative 
drug, inhibiting the mTOR-pathway with different applications in clinical medicine 
[101]. Also in endothelial cells, rapamycin reduces proliferation and thereby 
angiogenesis [86, 102]. In T-lymphocytes, complete arrest of cell expansion by 
rapamycin is only observed in cells lacking PIM kinases [83]. Cell migration implies 
assembly and disassembly of cell to cell and cell to matrix adhesion sites and 
rearrangements of the actin cytoskeleton and the ECM. PIM1 silencing by RNAi 
diminished endothelial migration in response to VEGF [66], but so far no data on 
PIM1-dependent rearrangement of cell-cell and cell-matrix adhesion is available. 
Therefore, we investigated PIM1’s involvement in endothelial cell proliferation with 
respect to rapamycin treatment and endothelial barrier integrity in wildtype and Pim1-
/- cells.    
We show, that proliferating Pim1-/- cells have an increased sensitivity to rapamycin. 
Furthermore, inhibition of the mTOR signaling pathway increased PIM1 cytosolic and 
nuclear protein levels. By overexpression of c-terminal truncated Pim1 mutants we 
found a region to be critical for intracellular localization of the kinase. Finally, 
overexpression of this minimal c-terminal truncation of Pim1 (FLAG-Pim1Δ276-313), 
which localizes to the nucleus, increased proliferation of Pim1-/- cells significantly.  
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Pim1 deletion and kinase inhibition attenuated endothelial cell detachment by 
trypsinization and increased total electrical resistance across the endothelial 
monolayer. Reintroduction of Pim1-cDNA into Pim1-/- cells partially but significantly 
restored electrical resistance to wildtype levels. Furthermore, Pim1 depleted 
endothelial cells had markedly reduced cell motility as shown in wound healing 
assays. On the level of gene regulation, this phenotype caused expressional 
changes of a subset of cell-cell attachment proteins and cell adhesion molecules. 
Additionally, protein abundance of -catenin and vinculin, at the adherens and tight 
junctions, was markedly increased. Intriguingly, ECM deposited by Pim1-/- cells alone 
was sufficient to induce Pim1-/- adhesion characteristics in wildtype cells.   
  Pim1 knockout increases sensitivity of MAEC proliferation to rapamycin.   10.1
During the past years rapamycin and rapalogues have emerged as anticancer drugs 
for several specific cancers. Nevertheless, these reagents have turned out to be less 
efficacious in tumor treatment than expected [103]. Our first observation in MAEC 
was a marked increase of PIM1 protein levels after rapamycin treatment (Fig.11). As 
PIM1 has been shown to inactivate cell cycle inhibitors such as p27Kip1 [77] or 
p21Cip1/Waf1 [78], we asked whether this could be a refractory mechanism to mTOR 
inhibition. Indeed, compared to wildtype cells, Pim1-/- MAEC proliferation showed a 
significantly increased sensitivity to rapamycin (Fig.10A). PIM kinases also mediate 
survival signaling by interaction with members of the BCL2 protein family [104] and 
partially through direct phosphorylation of  the pro-apoptotic protein BAD [65, 81]. To 
differentiate if decrease in Pim1-/- cell proliferation was partially due to cell death, we 
analyzed cell survival by FACS. However, no significant differences in apoptotic cell 
populations were observed and in conditions analyzed, the percentage of apoptotic 
cells was counted less than 2% (Fig.10B).      
PIM1 kinase cellular distribution is diverse. It has been found to be cytosolic, nuclear 
or both [2, 105]. The consequences of PIM1 subcellular localization are not yet 
elucidated. In cardiac explants from murine neonates and mice in the early adulthood 
PIM1 seems to shift from a predominantly nuclear to a more cytoplasmic localization, 
whereas in adults PIM1 expression is almost lost. However in a mouse model of 
chronic heart failure the percentage of nuclear PIM1 again markedly increased, which 
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was also the case in samples from failing human hearts [65]. In lymphoma cells PIM1 
appeared to be predominantly nuclear, which was not the case in normal lymph 
nodes [89]. Irradiation promoted nuclear translocation of PIM1 in radioresistant 
squamocellular cancers of head and neck [106]. Taken together cellular localization 
seems to influence the proto-oncogenic activity of PIM kinases, possibly by substrate 
specificity conferred by different subcellular localization. By immunostainings of 
MAEC we observed an increase in endogenous nuclear PIM1 after rapamycin 
treatment (Fig.11B). To investigate whether the upregulation of PIM1 protein levels 
and the increase of its nuclear abundance were mTOR specific, we treated Pim1+/+ 
MAEC with inhibitors of different signaling cascades. Quantification of PIM1 protein 
levels revealed a significant increase in PIM1 protein expression for rapamycin and 
AKT inhibitor IV treated cells in both, cytosol and nucleus. Also PI3K inhibition 
upregulated PIM1 expression levels, yet not significantly. Nevertheless, compared to 
untreated cells we found no significant difference in the subcellular distribution of 
PIM1 (cytosol vs. nucleus). Rapamycin and AKT inhibitor IV increased the whole cell 
PIM1 protein levels (Fig.11A).   
 Truncation of c-terminal residues beyond a specific Serine residue results 10.2
in PIM1 nuclear translocation. 
We were interested to dissect, whether overall increase in PIM1 protein levels or 
nuclear PIM1 alone is responsible for the significantly different proliferative response 
to rapamycin of Pim1+/+ and Pim1 -/- cells (Fig.10A and Fig.11). Ionov et al. proposed 
that half of the carboxy-terminus of PIM1 kinase is responsible for PIM1 nuclear 
translocation [89]. We performed in silico analysis to localize putative nuclear 
localization or export signals on the PIM1 protein sequence. However, we were not 
able to identify any promising sequence (data not shown).  
NFATc are gene regulatory proteins, which control T-cell activation. In resting cells, 
they are found in the cytosol in a phosphorylated state. Upon T-cell activation, 
calcineurin binds to and dephosphorylates NFATc, which is then imported into the 
nucleus [107]. Replacement of conserved Ser residues with Ala in a Serine-rich 
region (SRR) of NFATc’s increased their nuclear localization [108-110]. Vice versa 
mTOR has been shown to retain NFATc in the cytosol through basal phosphorylation 
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of the SRR [90]. PIM1 is known to positively influence transcriptional activity of 
NFATc1 on proliferation and survival [111]. Therefore we asked whether mTOR 
similarly regulates PIM1 cellular localization: Does PIM1 consist of an SRR, basally 
phosphorylated by mTOR, retaining PIM1 in the cytosol, which is abolished by mTOR 
inhibition through rapamycin? The PIM1 protein sequence is highly conserved in 
between species when comparing human, mouse, rat, bovine, frog and zebra fish 
sequences [89]. Sequence alignment revealed 7 Ser residues in the carboxy-terminal 
part, which could be putative phosphorylation targets (Fig.14). Pim1 cDNA was 
truncated at these particular residues and cloned into a pdsREDT3 C1 and a pCMV-
Tag 2A expression vector (Fig.12, 13). MAEC were transfected with both dsRED-
Pim1 and pCMV-Tag 2A-Pim1 constructs. MAEC expressing dsRED-Pim1 
displayed a higher percentage of nuclear positive endothelial cells, which was not 
significant in cells expressing dsRED-Pim1but again in cells expressing 
dsRED-Pim1andFig15Overall we observed a tendency to a higher 
percentage of nuclear PIM1 positive cells in cells expressing PIM1 truncated beyond 
Ser276. However, MAEC transfected with FLAG-Pim1, displayed an almost complete 
nuclear localization of PIM1 truncated beyond Ser 276 (Fig.16). Even though the 
results in both experiments were not completely congruent, there seems to be a 
critical site for PIM1 nuclear localization around Ser 276. We further performed site 
directed mutagenesis of Ser 276, Ser 227, Ser 261 and Ser 261/276 to Alanine or 
Glutamic acid, to mimic a phospho– and dephosphorylated state (data not shown). 
We could not observe such consistent results as for the truncation mutants. Possible 
explanations could be a more complex phosphorylation pattern, which includes other 
Serines also, or that there are still unknown motifs, which regulate the subcellular 
localization of PIM1. However phopshoproteomics could help to further investigate, 
whether there is a phosphorylation motif, which causes cytosolic retention or nuclear 
translocation. Another more likely explanation could be, that mTOR inhibition 
activates a parallel mitogenic signalling mechanism, which counteracts rapamycin 
treatment by upregulation of PIM1 protein expression.  
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 Nuclear PIM1 increases endothelial cell proliferation.  10.3
To dissect whether nuclear PIM1 affects endothelial proliferation, FLAG-Pim1wt  and 
FLAG-Pim1 were re-expressed in Pim1-/- cells and proliferation was measured 
(Fig. 17C). Indeed, MAEC expressing FLAG-Pim1 were more proliferative than 
cells transfected with FLAG-Pim1wt. This finding could possibly explain, the fact that 
Pim1-/- endothelial cell proliferation is more sensitive to rapamycin than the wildtype 
cell proliferation. 
 Hypothesis 10.4
Our results show that Pim1-/- endothelial cells are more sensitive to rapamycin in 
terms of proliferation. Furthermore we found an increase in PIM1 protein expression 
levels and thereby in nuclear PIM1 protein by inhibition of key proteins of the mTOR 
pathway, AKT and mTOR. Re-expression of c-terminally truncated Pim1, which 
located to the nucleus, markedly increased endothelial cell proliferation.  
Fig.25 shows a hypothetical model resulting from our observations. Through 
inhibition of the mTOR pathway by Akt inhibitor IV and rapamycin, endothelial  
 
 
 
 
 
 
 
 
 
 
 
 
 
proliferation decreases. A mechanism that has not been observed so far, then leads 
to increased PIM1 protein levels. Mechanistically this could be at the transcriptional, 
Figure 25. Hypothetical model of the regulation of PIM1 through inhibition of the
mTOR pathway.
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posttranscriptional, translational or posttranslational level [112, 113]. PIM1 protein 
levels increase in the cytosol and actively regulated or passively also nuclear PIM1 
protein levels increase. Finally, as we show, especially nuclear PIM1 seemed to 
increase proliferation, which would explain the enhanced resistance to rapamycin of 
Pim1+/+ cells.  
 PIM1 function in the nucleus 10.5
Nuclear PIM1 has been associated with resistance to cancer treatment, but little is 
known about the interactions of PIM1 in the nucleus. PIM1 has been shown to 
promote cell cycle progression by phosphorylation of the cell cycle inhibitors p27Kip1 
and p21Cip1/WAF1 [77, 78]. p27Kip1 phosphorylation induced cytoplasmic localization 
and subsequent proteasomal degradation of the cyclin-dependent-kinase inhibitor. 
p21Cip1/WAF1 also localizes to the cytoplasm, once phosphorylated by PIM1 kinase. 
Also c-MYC has been shown to cooperate with PIM1 in cell cycle progression and 
cell tumorigenesis [114-116]. However, only decades later additional mechanistic 
insight of this interaction was provided: In the nucleus, PIM1 phosphorylates histone 
H3 in HUVEC’s, which leads to MYC-driven transcription and cell transformation 
[117]. It has also been suggested that PIM1 phosphorylates heterochromatin protein 
1, a histone H3 binding transcriptional repressor, reducing its gene silencing function 
[118]. Additionally PIM1 appeared to be nuclear in radioresistant tumors [106] and 
the pathologically challenged myocard [65]. Interestingly preliminary data indicates, 
that in cells treated with rapamycin, we observe that dsRED-Pim1wt localizes in foci at 
the intersection of eu- and heterochromatin (data not shown). At these sites where 
active transcription takes place, many signaling kinases, such as PKB/AKT, S6K1 or 
JNK1, shuttle to the nucleus where they modify histones and influence the 
condensation state and thereby the transcriptional accessibilty of chromatin [119]. 
We speculate, that PIM1 may elicite its regulatory function in the cell nucleus through 
epigenetic regulation. The existence of such a PIM1-dependent transcriptional 
regulation is supported by data obtained from gene expression profiling of Pim1 
wildtype and Pim1-/- cells: The vast number (1598) of significantly (P<0.01) regulated 
genes when comparing wildtype and Pim1-/- MAECs found by gene expression 
profiling, suggests a more general rather than transcription factor-dependent type of 
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regulation mediated by PIM1 (see section 6.2.6). In cancer, aberrant silencing or 
activation of gene expression often occurs through epigenetic regulation, which 
triggers abnormal cell behaviour, such as malignant transformation but also changes 
in adhesive properties of cells [120, 121]. Two prominent mechanisms responsible for 
cancer development and progression, are promoter hypermethylation, which elicits 
gene silencing, and histone modifications, which determines the accessibilty of the 
transcription machinery to chromatin [121-123]. Regulation of the key genes involved 
in cell adhesion, we found to have a different expression pattern comparing Pim1-/- 
vs. Pim1+/+ cells, have been reported to be silenced by such mechanisms: The 
promoter of Cdh13 in various tumors and Jam2 in colorectal adenomas and 
carcinomas was found to be hypermethylated [124-126]. Icam1 in tumor endothelial 
cells and Itga7 expression in hepatoma cells has been shown to be epigenetically 
regulated through histone modifications [127, 128]. In the present study all these 
genes were found to be significantly upregulated in Pim1-/- cells (Table 5, Fig23). 
Nevertheless, further investigations are needed, also in cancer cell lines, to shed 
further light on PIM1’s potential role in epigenetic regulation of cell adhesion, tumor 
angiogenesis and metastasis. 
 
 Pim1 deletion increases endothelial cell adhesion and thereby affects cell 10.6
motility. 
In the present study we report that PIM1 plays a distinct role in endothelial cell-cell 
cohesion and cell-matrix adhesion. We demonstrate that Pim1 deletion and kinase 
inhibition slows endothelial cell detachment by trypsinization and increases total 
electrical resistance across the endothelial monolayer. Reintroduction of Pim1 cDNA 
into Pim1-/- cells partially but significantly restored electrical resistance to wildtype 
levels. Furthermore, Pim1 deletion in endothelial cells markedly reduced cell motility 
as shown in wound healing assays. This finding is consistent with an earlier report 
using cells derived from human prostate cancer or squamo-cellular carcinoma where 
Pim1 silencing decreased wound healing in vitro [75]. We therefore conclude that 
modulation of endothelial cell adhesion by Pim1 deletion, kinase inhibition and Pim1 
cDNA reintroduction into Pim1-/- cells is actually Pim1-specific. Most likely this 
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requires its classical serine-threonine kinase activity, as suggested earlier by Santio 
et al., since a similar PIM1 kinase inhibitor in human cancer cells slowed down cell 
motility [75].  
Cell migration is a complex, tightly regulated process that involves the dynamic 
formation and disassembly of distinct adhesion complexes [129, 130]. We therefore 
further dissected the characteristics of endothelial cell adhesion modulation by 
differentiating electrical resistance values and found that both cell-cell cohesion and 
cell-substrate adhesion were reinforced by Pim1 deletion.  
 Endothelial cell-cell junctions and focal adhesion structures are more 10.7
pronounced in Pim1 knockout cells. 
The intracellular domain of the adherens junctions effector protein VE–cadherin 
contains a distal binding site for β-catenin. β-catenin is linked to α-catenin, which may 
further interact with the cytoskeleton via α-actinin and vinculin [30, 97]. Finally, 
integrins directly adhere to the matrix substratum and connect to talin and vinculin, 
[131]. Interestingly, Pim1-/- cells exhibited more vinculin positive focal adhesion 
structures that spread throughout the entire endothelial cell surface, whereas 
wildtype cells displayed less vinculin positive streaks that were predominantly located 
laterally at cell junctions. Furthermore, Pim1-/- cells displayed abnormally enlarged -
catenin positive structures at cell-cell junctions than usually found in wildtype 
endothelial cells. Thus, Pim1 deletion reinforced connection complexes between cell-
to-cell junctions and focal adhesion structures, which might mechanically increase 
intercellular forces and tension [132]. While Pim1 deletion did not change overall -
catenin and vinculin protein levels, gene expression analysis demonstrated 
significant and strong regulation of matrix components (Col6a, Col11a) and cell to 
matrix (Itga7) and cell-to-cell attachment (Cdh13, Jam2) modulating genes. 
MetaCore™ analysis of all genes modulated by Pim1 deletion revealed WNT-
mediated cytoskeleton remodeling as the most significantly regulated biological 
process. 
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 Pim1 knockout-deposited matrix induces adhesion characteristics of Pim1 10.8
knockout cells in wildtype cells.  
Pim1-/- but not wildtype cells deposited a specific, COL6A3-containing matrix in fibre-
like structures on culture dish surfaces: Intriguingly, ECM deposited by Pim1-/- cells 
alone was sufficient to induce Pim1-/- adhesion characteristics in wildtype cells, with 
respect to cell detachment and adherens junction strengthening. This may be 
interpreted as one of the early events in the establishment of the Pim1-/- adhesion 
phenotype. Matrix-integrin mediated signals are transduced by the focal adhesion 
kinase (FAK) [30]. Thus, enhanced matrix-integrin interactions in Pim1-/- cells may 
increase vinculin-containing focal adhesion structures and modulate FAK signaling. 
Observations in different model systems suggest a complex and dynamic cross talk 
between the focal adhesion kinase and the WNT-signaling pathway [133, 134]. 
Canonical WNT-signalling promotes dissociation of -catenin from junctional 
complexes to the nucleus, which also results in reduced cell-cell adhesion in 
tumorigenesis [23]. As we show in Fig. 5B, Pim1-/- MAEC display pronounced -
catenin clusters at the cell to cell borders, which could be hypothetically explained by 
reduced WNT-signalling in these cells. This is also demonstrated in FAK kinase dead 
mutant mice where vascular permeability and angiogenic growth factor VEGF failed 
to induce dissociation of -catenin from adherens junction complexes [135]. 
Intriguingly we found that Pim1-/- cell-deposited matrix also enhanced -catenin-
containing structures at cell-cell contacts of wildtype MAEC. Therefore, we assume 
that matrix- induced signalling may repress WNT signaling in Pim1-/- endothelium 
preventing redistribution of -catenin from adherens junctions to the nucleus, thereby 
enhancing cell-cell cohesion. 
 Conclusion  10.9
Taken together, we demonstrate two distinct novel roles for PIM1 in endothelial cells. 
First, we show that Pim1 causes endothelial proliferation to be more sensitive to 
rapamycin. In wildtype cells we show that rapamycin treatment leads to an increase 
in PIM1 protein levels in the cytosol and the nucleus. By transfection of different c-
terminal truncations of PIM1 we found a region around Ser276 to be critical for 
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nuclear localization of the kinase. Re-expression of this truncation mutant in Pim1-/- 
cells significantly increased proliferation compared to cells expressing wildtype Pim1. 
Additionally, preliminary data indicates that this effect is rapamycin insensitive. We 
conclude that PIM1 nuclear abundance increases endothelial cell proliferation, in an 
at least partially rapamycin independent way. Therefore, PIM1 kinase inhibitors might 
be useful angiogenic inhibitors in combination with rapalogues. Especially in cancer 
known to be positively stimulated by PIM1, or in cancer insensitive to rapamycin. 
Furthermore the subcellular localization of PIM1 could be a prognostic marker for 
tumor progression and drug response.  
Second, we show a novel role of PIM1 in the regulation of endothelial cell-cell 
cohesion and cell-matrix adhesion, which likely involves a matrix-initiated response, 
involving collagen, alteration in vinculin-containing focal adhesion structures and 
pronounced -catenin-containing junctional complexes. This is accompanied by 
alterations in cell adhesion gene regulation. A hyperadhesive endothelial Pim1-/- 
phenotype might be useful to promote endothelial barrier integrity, restrict 
angiogenesis in growing tumors and impede invasion and metastatic spread of 
malignant cells through the endothelial monolayer. 
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14 ABBREVIATIONS 
4EBP   Eukaryotic initiation factor (eIF) 4E-binding protein 1 
BAD   B-cell-lymphoma-2-antagonist of cell death 
Cdh13  Cadherin 13 
C-TAK1   Protein kinase Cdc25 C-associated kinase 1 
C-terminus  Carboxy-terminus 
DMEM  Dulbecco’s modified eagle medium 
EC   Extracellular cadherin 
ECIS   Electric cell-substrate impedance sensing 
ECM   Extracellular matrix 
EIF4E   Eukaryotic translation-initiation factor 4E  
F-actin  Filamentous actin 
FACS   Fluorescence-activated cell sorting 
FAK   Focal adhesion kinase 
FCS   Fetal calf serum 
FDCP   Factor-Dependent Cell Progenitor 
FGF   Fibroblast growth factor 
FITC   Fluoresceinisothiocyanat 
FKBP12  12-kDa FK506-binding protein  
FRAP   FKBP12-rapamcyin-associated protein 
GbL    G-protein b-subunit like protein 
HIF   Hypoxia inducible transcription factor 
HP1   Heterochromatin protein 1 
HUVEC  Human umbilical vein endothelial cells 
IRES   Internal ribosomal entry site 
IRS-1   Insulin receptor substrate 1 
JAK-STAT  Janus kinase and signal transducer and activator of transcription 
JAM2   Junctional adhesion molecule 2 
MAEC  Mouse aortic endothelial cells 
mLST8  Mammalian lethal with SEC13 protein 8  
mSIN1  Mammalian stress-activated map kinase-interacting protein 1 
mTOR  Mammalian target of rapamycin 
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mTORC2  mTOR complex 1 
mTRORC1  mTOR complex  
NFATc4  Nuclear factor of activated T-cells cytoplasmic 4 
N-terminus  Amino-terminus 
o/n   Overnight 
PDK1   Phosphoinositide-dependent kinase 1 
PI   Propidium iodide 
PI3K   Phosphatidylinositol 3-kinase 
PIM1   Proviral integration site for moloney leukemia virus 1 
PKB   Protein kinase B 
PRAS40  Pro-rich Akt substrate 
RAFT   Rapamycin and FKBP12 target 
RAPT   Rapamycin target 
Raptor  Regulatory associated protein of mTOR 
Rictor   Rapamycin-insensitive companion of mTOR 
p70 S6 kinase p70 ribosomal S6 protein kinase 1 
SEP   Sirolimus effector protein 
SOCS   Suppressor of cytokine signalling 
SRR   Serine rich region 
STAT5  Signal transducer and activator of transcription 5  
TOR   Target of rapamycin 
TSC1   Tuberous sclerosis complex 1 
TSC2   Tuberous sclerosis complex 2 
VE-cadherin  Vascular endothelial cadherin 
VEGF   Vascular endothelial growth factor  
WNT   Wingless-int 
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